2-[4-(3-氯苯基)-1-哌嗪基]-1-苯基乙酮 | 250714-00-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-[4-(3-氯苯基)-1-哌嗪基]-1-苯基乙酮
• 英文名称: 2-(4-(3-chlorophenyl)piperazin-1-yl)-1-phenylethan-1-one
• 英文别名: 2-(4-(3-chlorophenyl)piperazin-1-yl)-1-phenylethanone；2-[4-(3-chlorophenyl)piperazin-1-yl]-1-acetophenone；2-[4-(3-Chlorophenyl)piperazino]-1-phenyl-1-ethanone；2-[4-(3-chlorophenyl)piperazin-1-yl]-1-phenylethanone
• CAS: 250714-00-2
• 化学式: C₁₈H₁₉ClN₂O
• 分子量: 314.815
• InChiKey: NYVAYBJBTHCYHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alpha-氯乙酰苯 、 1-(3-氯苯基)哌嗪 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以87%的产率得到2-[4-(3-氯苯基)-1-哌嗪基]-1-苯基乙酮
  参考文献：
  名称：

  Design, Synthesis and Biological Activity Evaluation of Arylpiperazine Derivatives for the Treatment of Neuropathic Pain

  摘要：

  在这项工作中，一系列苯基哌嗪衍生物被合成并通过体内药理学试验进行筛选。在测试的化合物中，2-(4-(3-(三氟甲基)苯基)哌嗪-1-基)-1-苯乙酮（18）和2-(4-(2,3-二甲基苯基)哌嗪-1-基)-1-苯乙酮（19）在小鼠扭体和大鼠热板实验中表现出强大的镇痛活性。在扭体实验中，它们相对于对照组显示出超过70%的抑制率，且在热板测试中分别将延迟时间增加了116.0%和134.4%。此外，化合物18在没有镇静副作用的情况下，在福尔马林痛和神经病理性痛模型中也表现出活性。

  DOI：

  10.3390/molecules16075785

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20190194163A1

  公开（公告）日：2019-06-27

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
• Design, Synthesis and Biological Activity Evaluation of Arylpiperazine Derivatives for the Treatment of Neuropathic Pain
  作者：Yin Chen、Guan Wang、Xiangqing Xu、Bi-Feng Liu、Jianqi Li、Guisen Zhang

  DOI：10.3390/molecules16075785

  日期：——

  In this work, a series of arylpiperazine derivatives were synthesized and screened by in vivo pharmacological trials. Among the tested compounds, 2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)-1-phenylethanone (18) and 2-(4-(2,3-dimethylphenyl)piperazin-1-yl)-1-phenylethanone (19) exhibited potent analgesic activities in both the mice writhing and mice hot plate tests. They showed more than 70% inhibition relative to controls in the writhing test, and increased latency by 116.0% and 134.4%, respectively, in the hot plate test. Furthermore, compound 18 was also active in the models of formalin pain and neuropathic pain without sedative side effects.

  在这项工作中，一系列苯基哌嗪衍生物被合成并通过体内药理学试验进行筛选。在测试的化合物中，2-(4-(3-(三氟甲基)苯基)哌嗪-1-基)-1-苯乙酮（18）和2-(4-(2,3-二甲基苯基)哌嗪-1-基)-1-苯乙酮（19）在小鼠扭体和大鼠热板实验中表现出强大的镇痛活性。在扭体实验中，它们相对于对照组显示出超过70%的抑制率，且在热板测试中分别将延迟时间增加了116.0%和134.4%。此外，化合物18在没有镇静副作用的情况下，在福尔马林痛和神经病理性痛模型中也表现出活性。